Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts [Seeking Alpha]
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: Seeking Alpha
SGMT's lead asset, denifanstat, is advancing in combination studies with resmetirom for MASH, with key data expected by early 2026. The FDA's acceptance of noninvasive endpoints like FibroScan could accelerate SGMT's trial timelines and reduce development complexity. Valuation remains attractive relative to peers, but clinical and regulatory risks around denifanstat and SGMT's pipeline remain significant near-term considerations. Ekaterina Dorozhkina/iStock via Getty Images Thesis Since my previous coverage on Sagimet Biosciences Inc ( NASDAQ: SGMT ), the stock has traded a bit sideways, down just 2% over the past month. However, last month we got some very nice updates from management on This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not r
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare ConferenceGlobeNewswire
- Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts [Seeking Alpha]Seeking Alpha
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/14/25 - Form SCHEDULE
- SGMT's page on the SEC website